• Recombinant Mouse M-CSF, Tag Free for Macrophage Assays

  2026-09-23

  Use Recombinant Mouse M-CSF, Tag Free to build a consistent mouse macrophage platform for testing tumor–immune interactions and antigen presentation. This workflow connects macrophage preparation to a cholangiocarcinoma study of PDHA1 succinylation while distinguishing practical assay recommendations from the paper’s findings.

• Meropenem Workflows for Infection Research

  2026-09-23

  Build more informative infection assays with Meropenem by combining MIC testing, time-kill kinetics, resistance surveillance, and formulation controls. This workflow distinguishes broad antibacterial coverage from isolate-specific susceptibility and supports Gram-negative, Gram-positive, anaerobic, and septicemia treatment research without confusing preclinical findings with clinical guidance.

• WTAP–GLS Splicing Drives Ferroptosis Resistance in HCC

  2026-09-22

  The reference study identifies an EGFR–AKT–WTAP–GLS pathway that rewires glutamine metabolism and protects hepatocellular carcinoma cells from ferroptosis. Its central advance is linking WTAP phosphorylation and m6A-dependent alternative splicing to the preferential production of the GAC glutaminase isoform, providing a mechanistic basis for therapeutic strategies targeting metabolic plasticity.

• ATRX Loss Sensitizes High-Grade Glioma to RTK Inhibitors

  2026-09-22

  The 2022 Cancers study linked ATRX deficiency in high-grade glioma cells to increased sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors. Its drug-screening and combination-treatment results support stratifying glioma models and clinical trial analyses by ATRX status, while recognizing that the evidence remains primarily preclinical.

• Aβ25-35 Workflows for Neurotoxicity Research

  2026-09-21

  Build reproducible cell-based Alzheimer’s disease neurotoxicity models with Aβ25-35 while tracking mitochondrial injury, oxidative stress, apoptosis, and microglial signaling. This practical guide connects peptide handling to mechanistic assays inspired by the FLOT1–FOSL2–EphA2 pathway and offers troubleshooting strategies for aggregation, vehicle effects, and variable cell responses.

• WTAP–GLS Splicing and Ferroptosis in HCC

  2026-09-21

  The reference study identifies an EGFR–AKT–WTAP mechanism that redirects GLS pre-mRNA splicing toward the GAC isoform, increasing glutamine utilization and antioxidant capacity in hepatocellular carcinoma. Its integrated metabolomic, transcriptomic, molecular, cellular, animal, and clinical analyses connect m6A-dependent RNA processing with ferroptosis resistance and tumor progression.

• Pioglitazone PPARγ Assay Workflows

  2026-09-20

  Build reproducible PPARγ experiments across beta-cell, macrophage, intestinal inflammation, and neurodegeneration models with Pioglitazone. This guide combines receptor-level assay design, DSS inflammatory bowel disease workflows, formulation advice, and troubleshooting for stronger mechanistic conclusions.

• Genotyping Kit for Target Alleles: Lab Guide

  2026-09-19

  This scenario-based guide explains how SKU K1026 can simplify PCR-based allele verification in insects, tissues, fish, and cells when assay reproducibility is affected by uncertain genotype or slow DNA preparation. It connects practical workflow decisions with appropriate controls, storage requirements, and the limitations of applying genotyping tools to cell viability and colitis research.

• PPARγ, STAT Signaling, and DSS-Induced IBD

  2026-09-18

  The reference study shows that PPARγ activation reduces DSS-induced intestinal inflammation by shifting macrophages away from an M1 phenotype toward an M2-associated state through coordinated changes in STAT-1 and STAT-6 phosphorylation. Its combined cell-culture and mouse-model design provides a useful framework for connecting nuclear-receptor signaling, macrophage plasticity, and intestinal barrier repair while highlighting important limits on translation.

• Dehydroabietic Acid in Adipocyte Assays

  2026-09-18

  Use Dehydroabietic acid as a controlled dual PPAR-α/γ agonist to connect receptor signaling with lipid handling and insulin-response phenotypes in adipocyte models. This workflow also shows how to pair small-molecule perturbation with adipocyte-targeted CRISPRi without conflating pharmacology with gene silencing.

• Tunable Human Intestinal Organoids for Cell-Fate Control

  2026-09-17

  Yang and colleagues developed a chemically tunable human small-intestinal organoid system that maintains strong proliferation while increasing epithelial cell diversity. The study shows how stemness enhancement, reversible fate control, and targeted Wnt, Notch, BMP, and BET-related modulation can reduce the need to separate organoid expansion from differentiation.

• Pioglitazone: PPARγ Agonist Workflow Guide

  2026-09-17

  Pioglitazone gives researchers a practical way to connect PPARγ activation with macrophage polarization, intestinal barrier integrity, and metabolic transcriptional responses. This workflow guide translates a DSS-induced inflammatory bowel disease study into assay design, formulation, controls, and troubleshooting decisions.

• Tricine-SDS-PAGE Gel Preparation Kit Guide

  2026-09-16

  The Tricine-SDS-PAGE Gel Preparation Kit is intended for resolving low-molecular-weight proteins and peptides that are poorly separated by conventional Tris-SDS-PAGE. It supports research protein electrophoresis in denaturing or non-denaturing workflows, but it is not intended for diagnostic, clinical, or medical use.

• Stable Yeast Expression of Exendin-4 for T2D

  2026-09-16

  A 2024 Frontiers in Systems Biology study established a proof of concept for producing Exendin-4 in Escherichia coli and Saccharomyces cerevisiae, with the clearest validation obtained from a chromosomally integrated yeast strain. Detection at the expected peptide size and confirmation by immunoassay support further investigation of locally propagated production, but do not yet demonstrate bioactivity, oral delivery, or therapeutic equivalence.

• Ertugliflozin, Brain Insulin Signaling, and Tau

  2026-09-15

  This study tested whether the SGLT2 inhibitor ertugliflozin could reduce cognitive and molecular abnormalities in a streptozotocin-induced rat model of brain insulin resistance. Its main contribution is linking improved behavioral performance with reduced tau hyperphosphorylation, altered IRS-1/Akt/GSK3β signaling, and protection of cholinergic, mitochondrial, apoptotic, and synaptic endpoints.

8684 records 1/579 page Next 12345 下5页 Last page